Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income / (loss)	$ 1,881,000	$ (379,000)
Adjustments to reconcile net income / (loss) to net cash used in operating activities:
Depreciation and amortization	8,000	13,000
Asset Sale to Healgen	(2,114,000)	0
Provision for bad debt	0	(1,000)
Consulting fee paid with restricted stock	0	15,000
Changes in:
Accounts receivable	(7,000)	186,000
Inventory	0	24,000
Prepaid expenses and other current assets	83,000	(11,000)
Right of use asset	0	9,000
Accounts payable	24,000	161,000
Accrued expenses and other current liabilities	(176,000)	(17,000)
Right of use liability	0	(9,000)
Wages payable	(62,000)	(4,000)
Net cash used in operating activities	(363,000)	(13,000)
Cash Flows from investing activities
Business Sale, net proceeds	247,000	0
Net cash provided by investing activities	247,000	0
Cash flows from financing activities:
Payments on debt financing	(100,000)	0
Proceeds from debt financing	250,000	0
Proceeds from lines of credit	0	462,000
Payments on lines of credit	0	(547,000)
Net cash provided by / (used in) financing activities	150,000	(85,000)
Net change in cash and cash equivalents	34,000	(98,000)
Cash and cash equivalents - beginning of period	34,000	115,000
Cash and cash equivalents - end of period	68,000	17,000
Non-Cash transactions:
Non-Cash transactions: Consulting fee paid with restricted stock	0	15,000
Cash paid for interest	$ 41,000	$ 46,000